Artivion, INC Form 4 insider transactions

Jean F. Holloway, SVP and General Counsel of Artivion, Inc. (AORT), reported the sale of 8,748 shares of common stock at $29 per share, executed under a Rule 10b5-1 trading plan.

Artivion, Inc. Director Anthony B. Semedo filed an amended Form 4 to correct an administrative error regarding his beneficial ownership of common stock following a sale of 2,600 shares on May 23, 2025.

Artivion, Inc. Director Anthony B. Semedo was granted 6,325 shares of common stock as a Restricted Stock Award, vesting in May 2026.

ARTIVION, Inc. Director Marna Borgstrom was granted 6,325 shares of common stock as a Restricted Stock Award, increasing her direct beneficial ownership to 49,088 shares.

Artivion, Inc. Director Daniel J. Bevevino was granted 6,325 shares of common stock as a Restricted Stock Award, vesting in May 2026.

Artivion Inc. Director Thomas F. Ackerman was granted 6,325 shares of common stock as part of an equity incentive plan, vesting in May 2026.

Artivion, Inc. director Jon W. Salveson was granted 6,325 shares of common stock as a Restricted Stock Award, vesting on May 22, 2026.

ARTIVION, Inc. Director Elizabeth A. Hoff was granted 6,325 shares of common stock as part of an equity incentive plan, increasing her total beneficial ownership to 31,389 shares.

ARTIVION, INC. Director Jeffrey H. Burbank was granted 6,325 shares of common stock as part of an equity incentive plan, increasing his total beneficial ownership to 53,796 shares.

ARTIVION, Inc. Director James Bullock was granted 6,325 shares of common stock on May 22, 2025, as part of the company's Equity and Cash Incentive Plan.

Artivion, Inc. Director Anthony B. Semedo reported the sale of 2,600 shares of common stock for approximately $74,000, as part of a pre-arranged trading plan.

Jean F. Holloway, SVP, General Counsel of Artivion, Inc., sold 9,926 shares of common stock at $29 per share on May 21, 2025.

Marshall S. Stanton, SVP of Clinical & MD Affairs at Artivion, Inc., reported the sale of common stock on May 9, 2025.

Jean F. Holloway, SVP and General Counsel of Artivion, Inc., reports the sale of 18,020 shares of common stock and the exercise of stock options for 19,092 shares.

Chief Commercial Officer John E. Davis exercised stock options and sold shares of Artivion, Inc. on March 11, 2025, according to a Form 4 filing.

Artivion's CEO, James Mackin, reports transactions involving common stock and stock options, including acquisitions, disposals, and exercises, under a pre-arranged 10b5-1 trading plan.

Amy Horton, VP, Chief Accounting Officer of Artivion, Inc., reports acquisition of 10,261 shares and disposition of 1,048 shares of common stock on March 6, 2025.

Executive VP and CFO Lance A. Berry reports acquisition and disposal of Artivion, Inc. stock related to performance stock units.

Chief Commercial Officer John E. Davis reports acquisition and disposal of Artivion, Inc. stock related to performance stock units.

Marshall S. Stanton, SVP of Clinical & MD Affairs at Artivion, Inc., reports the acquisition and disposal of company stock related to performance stock units.

Jean F. Holloway, SVP and General Counsel of Artivion, Inc., reports acquisition of shares through performance stock units and sale of shares to cover tax obligations.

Jean F. Holloway, SVP, General Counsel of Artivion, Inc., sold 472 shares of common stock at a price of $25.285 on March 5, 2025.

Director Anthony B. Semedo reports purchasing additional Artivion, Inc. shares for his and his spouse's IRA accounts.

Marshall S. Stanton, SVP, Clinical & MD Affairs at Artivion, Inc., reports acquiring 18,398 shares of common stock on February 28, 2025.

Artivion's CEO, James P. Mackin, reports acquiring 98,524 shares of common stock on February 28, 2025, bringing his total holdings to 762,406 shares.

Amy Horton, VP, Chief Accounting Officer of Artivion, Inc., reports the acquisition of 6,297 shares of restricted stock on February 28, 2025, as part of the company's Equity and Cash Incentive Plan.

Jean F. Holloway, SVP and General Counsel of Artivion, Inc., reports the acquisition of 23,416 shares of restricted stock on February 28, 2025.

Chief Commercial Officer of Artivion, Inc., John E. Davis, reports acquiring 24,301 shares of common stock on February 28, 2025.

Lance A. Berry, Executive VP and CFO of Artivion, Inc., reports acquiring 34,435 shares of common stock on February 28, 2025.

Amy Horton, VP, Chief Accounting Officer of Artivion, Inc., sold shares of common stock on February 24, 2025, to cover tax withholding obligations upon the vesting of restricted stock units.